Literature DB >> 25564714

In vitro and in vivo conditional sensitization of hepatocellular carcinoma cells to TNF-induced apoptosis by taxol.

V G Minero1, D De Stefanis, P Costelli, F M Baccino, G Bonelli.   

Abstract

High mortality among hepatocellular carcinoma (HCC) patients reflects both late diagnosis and low curability, due to pharmacoresistance. Taxol (TAX) is toxic for many human HCC-derived cell lines, yet its clinical efficacy on HCCs is poor. Combining TAX with other drugs appears a promising possibility to overcome such refractoriness. We analyzed whether combining tumor necrosis factor (TNF) with TAX would improve their toxicity. Human HCC-derived cell lines were treated with TAX or TNF, alone or combined. Apoptosis was assessed by morphology and flow-cytometry. Several pro- and anti-apoptotic molecules were evaluated by western blotting and/or enzymatic assay. After a 24 hour treatment, TNF was ineffective and TAX modestly cytotoxic, whereas HCC cells were conditionally sensitized to TNF by TAX. Indeed some relevant parameters were shifted to a prodeath setting: TNF-receptor 1 was increased, SOCS3, c-FLIP and pSTAT3 were markedly downregulated. These observations provide a significant clue to critically improve the drug susceptibility of HCC cells by combining 2 agents, TAX and TNF. The sequential application of TAX at a low dosage followed by TNF for only a short time triggered a strong apoptotic response. Of interest, prior TAX administration could also sensitize to TNF-induced apoptosis in the Yoshida AH-130 hepatoma transplanted in mice. Therefore, scrutinizing the possibility to develop similar combination drug regimens in suitable preclinical models seems highly advisable.

Entities:  

Keywords:  COL, colchicine; DAPI, 4,6-diamidino-2-phenylindole dihydrochloride; HCC, hepatocellular carcinoma; NOC, nocodazole; SOCS3; SOCS3, suppressor of cytokine signaling 3; STAT3, signal transducer and activator of tanscription 3; TAX; TAX, taxol (paclitaxel); TNF; TNF, tumor necrosis factor-α; TNF-R1, TNF-receptor 1; TRAIL, tumor necrosis factor-related apoptosis-inducing ligand; apoptosis; hepatocellular carcinoma

Mesh:

Substances:

Year:  2015        PMID: 25564714      PMCID: PMC4614628          DOI: 10.1080/15384101.2014.1000695

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  45 in total

Review 1.  Microtubules as a target for anticancer drugs.

Authors:  Mary Ann Jordan; Leslie Wilson
Journal:  Nat Rev Cancer       Date:  2004-04       Impact factor: 60.716

2.  TRAIL, FasL and a blocking anti-DR5 antibody augment paclitaxel-induced apoptosis in human non-small-cell lung cancer.

Authors:  Christine Odoux; Andreas Albers; Andrew A Amoscato; Michael T Lotze; Michael K K Wong
Journal:  Int J Cancer       Date:  2002-02-01       Impact factor: 7.396

3.  Growth-inhibiting effects of taxol on human liver cancer in vitro and in nude mice.

Authors:  Jin-Hui Yuan; Ru-Ping Zhang; Ru-Gang Zhang; Li-Xia Guo; Xing-Wang Wang; Dan Luo; Yong Xie; Hong Xie
Journal:  World J Gastroenterol       Date:  2000-04       Impact factor: 5.742

4.  Suppression of SOCS3 increases susceptibility of renal cell carcinoma to interferon-α.

Authors:  Shintaro Tomita; Kei Ishibashi; Koichi Hashimoto; Takashi Sugino; Tomohiko Yanagida; Nobuhiro Kushida; Keiichi Shishido; Ken Aikawa; Yuka Sato; Tatsuo Suzutani; Osamu Yamaguchi
Journal:  Cancer Sci       Date:  2010-11-05       Impact factor: 6.716

5.  Intracellular free iron and acidic pathways mediate TNF-induced death of rat hepatoma cells.

Authors:  R Autelli; S Crepaldi; D De Stefanis; M Parola; G Bonelli; F M Baccino
Journal:  Apoptosis       Date:  2005-08       Impact factor: 4.677

6.  TRAIL inactivates the mitotic checkpoint and potentiates death induced by microtubule-targeting agents in human cancer cells.

Authors:  Mijin Kim; Jessica Liao; Melissa L Dowling; K Ranh Voong; Sharon E Parker; Shulin Wang; Wafik S El-Deiry; Gary D Kao
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

7.  The growth inhibition of liver cancer cells by paclitaxel and the involvement of extracellular signal-regulated kinase and apoptosis.

Authors:  Jun-Ichi Okano; Takakazu Nagahara; Kazuya Matsumoto; Yoshikazu Murawaki
Journal:  Oncol Rep       Date:  2007-05       Impact factor: 3.906

8.  JNK activation is required for TNFα-induced apoptosis in human hepatocarcinoma cells.

Authors:  Valerio Giacomo Minero; Amina Khadjavi; Paola Costelli; Francesco Maria Baccino; Gabriella Bonelli
Journal:  Int Immunopharmacol       Date:  2013-06-07       Impact factor: 4.932

9.  Synergistic effects of IAP inhibitor LCL161 and paclitaxel on hepatocellular carcinoma cells.

Authors:  Aiping Tian; George S Wilson; Stefanus Lie; Guang Wu; Zenan Hu; Lionel Hebbard; Wei Duan; Jacob George; Liang Qiao
Journal:  Cancer Lett       Date:  2014-06-27       Impact factor: 8.679

10.  Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks.

Authors:  Michael J Lee; Albert S Ye; Alexandra K Gardino; Anne Margriet Heijink; Peter K Sorger; Gavin MacBeath; Michael B Yaffe
Journal:  Cell       Date:  2012-05-11       Impact factor: 41.582

View more
  5 in total

1.  Paclitaxel impairs adipose stem cell proliferation and differentiation.

Authors:  Rachel L Choron; Shaohua Chang; Sophia Khan; Miguel A Villalobos; Ping Zhang; Jeffrey P Carpenter; Thomas N Tulenko; Yuan Liu
Journal:  J Surg Res       Date:  2015-03-18       Impact factor: 2.192

2.  Multiple Functions of Cellular FLIP Are Essential for Replication of Hepatitis B Virus.

Authors:  Ah Ram Lee; Keo-Heun Lim; Eun-Sook Park; Doo Hyun Kim; Yong Kwang Park; Soree Park; Dong-Sik Kim; Gu-Choul Shin; Hong Seok Kang; Juhee Won; Heewoo Sim; Yea Na Ha; Byeongjune Jae; Seong Il Choi; Kyun-Hwan Kim
Journal:  J Virol       Date:  2018-07-31       Impact factor: 5.103

3.  LCL161 increases paclitaxel-induced apoptosis by degrading cIAP1 and cIAP2 in NSCLC.

Authors:  Chengcheng Yang; Huangzhen Wang; Boxiang Zhang; Yimeng Chen; Yamin Zhang; Xin Sun; Guodong Xiao; Kejun Nan; Hong Ren; Sida Qin
Journal:  J Exp Clin Cancer Res       Date:  2016-09-30

4.  Inhibition of kinesin family member 20B sensitizes hepatocellular carcinoma cell to microtubule-targeting agents by blocking cytokinesis.

Authors:  Xinran Liu; Yangkai Li; Xia Zhang; Xin-Yuan Liu; Anlin Peng; Yuchen Chen; Lijing Meng; Hong Chen; Yu Zhang; Xiaoping Miao; Ling Zheng; Kun Huang
Journal:  Cancer Sci       Date:  2018-10-04       Impact factor: 6.716

5.  Release of c-FLIP brake selectively sensitizes human cancer cells to TLR3-mediated apoptosis.

Authors:  Lugain Alkurdi; François Virard; Béatrice Vanbervliet; Kathrin Weber; Florent Toscano; Marc Bonnin; Nolwenn Le Stang; Sylvie Lantuejoul; Olivier Micheau; Toufic Renno; Serge Lebecque; Yann Estornes
Journal:  Cell Death Dis       Date:  2018-08-29       Impact factor: 8.469

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.